CYLD Antibodies

Target Information

CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.

Synonyms

2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; Cyld; CYLD lysine 63 deubiquitinase; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); deubiquitinating enzyme CYLD; EAC; FLJ20180; FLJ31664; FLJ78684; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Rp1; Rp1h; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; ubiquitin-specific-processing protease CYLD; Unknown (protein for MGC:137952); USPL2